Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Core Insights - Marker Therapeutics, Inc. has made significant advancements in its lead therapy MT-601, showing a 78% objective response rate in patients with refractory lymphomas, including durable complete responses [1][2] - The company secured over $13 million in non-dilutive funding from CPRIT and NIH to support its clinical programs for pancreatic and lymphoma treatments [1][2] - The USAN and INN committees approved "neldaleucel" as the nonproprietary name for MT-601, indicating progress in regulatory recognition [1][12] Program Updates - MT-601 is currently being evaluated in the Phase 1 APOLLO study for patients with anti-CD19 CAR-T relapsed lymphoma, with no reported dose-limiting toxicities and a favorable safety profile [5][12] - The APOLLO study reported that 7 out of 9 patients achieved objective responses, with 4 patients demonstrating complete responses [5] - The company plans to launch a clinical program for MT-601 in metastatic pancreatic cancer in the second half of 2025, supported by $2 million from NIH and $9.5 million from CPRIT [5][12] Financial Highlights - As of December 31, 2024, Marker Therapeutics had cash and cash equivalents of $19.2 million, which is expected to fund operations into Q1 2026 [7] - Research and development expenses increased to $13.5 million in 2024 from $10.4 million in 2023, while general and administrative expenses decreased to $4.2 million from $7.5 million [8] - The company reported a net loss of $10.7 million for the year ended December 31, 2024, compared to a net loss of $8.2 million in 2023 [8][17] Corporate Highlights - The company completed a $16.1 million private placement to support the clinical advancements of the Phase 1 APOLLO study, involving participation from notable investors [12] - Marker Therapeutics is focused on cash preservation and disciplined execution to maximize the impact of its clinical programs as it moves into 2025 [2][12] - The company aims to introduce novel T cell therapies to the market, prioritizing operational excellence and financial resource preservation [10]